Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Precigen, Inc. (PGEN : NSDQ)

• Company Description    Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland. Number of Employees: 143

• Price / Volume Information    Yesterday's Closing Price: $1.70 Daily Weekly Monthly 20 Day Moving Average: 1,674,281 shares Shares Outstanding: 295.18 (millions) Market Capitalization: $501.81 (millions) Beta: 1.78 52 Week High: $2.17 52 Week Low: $0.65 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.39% 7.08% 12 Week 18.06% 2.34% Year To Date 51.79% 43.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 20374 Seneca Meadows Parkway - Germantown,MD 20876 USA ph: 301-556-9900 fax: - investors@precigen.com http://www.precigen.com

• General Corporate Information    Officers Helen Sabzevari - Chief Executive Officer Randal J. Kirk - Executive Chairman Harry Thomasian Jr. - Chief Financial Officer Nancy H. Agee - Director Cesar L. Alvarez - Director Peer Information Precigen, Inc. (CORR.) Precigen, Inc. (RSPI) Precigen, Inc. (CGXP) Precigen, Inc. (BGEN) Precigen, Inc. (GTBP) Precigen, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74017N105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 295.18 Most Recent Split Date: (:1) Beta: 1.78 Market Capitalization: $501.81 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.21 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 119.45 EPS Growth vs. Year Ago Period: 30.00% vs. Previous Quarter: -75.00% Sales Growth vs. Year Ago Period: 25.92% vs. Previous Quarter: 12.69% ROE 06/30/25 - - 03/31/25 - -279.20 12/31/24 - -150.24 ROA 06/30/25 - - 03/31/25 - -79.74 12/31/24 - -80.52 Current Ratio 06/30/25 - - 03/31/25 - 3.53 12/31/24 - 4.76 Quick Ratio 06/30/25 - - 03/31/25 - 3.53 12/31/24 - 4.76 Operating Margin 06/30/25 - - 03/31/25 - -2,043.66 12/31/24 - -2,240.00 Net Margin 06/30/25 - - 03/31/25 - -3,728.87 12/31/24 - -3,216.18 Pre-Tax Margin 06/30/25 - - 03/31/25 - -3,770.86 12/31/24 - -3,261.86 Book Value 06/30/25 - - 03/31/25 - -0.05 12/31/24 - 0.13 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©